Pretreatment tables predicting pathologic stage of locally advanced prostate cancer

European Urology

Volumn 67, Issue 2, 2015, Pages 319-325

  Joniau, Steven ^a   Spahn, Martin ^b   Briganti, Alberto ^c   Gandaglia, Giorgio ^c   Tombal, Bertrand ^d   Tosco, Lorenzo ^a   Marchioro, Giansilvio ^e   Hsu, Chao Yu ^a   Walz, Jochen ^f   Kneitz, Burkhard ^g   Bader, Pia ^h   Frohneberg, Detlef ^h   Tizzani, Alessandro ⁱ   Graefen, Markus ^f   Van Cangh, Paul ^d   Karnes, R Jeffrey ^j   Montorsi, Francesco ^c   Van Poppel, Hein ^a   Gontero, Paolo ⁱ  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF BERN   (Switzerland)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h General Hospital Karlsruhe   (Germany)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j MAYO CLINIC   (United States)

more..

Author keywords

Locally advanced prostate cancer; Pretreatment tables; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; COHORT ANALYSIS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PELVIS LYMPHADENECTOMY; POSTOPERATIVE PERIOD; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RETROSPECTIVE STUDY; TUMOR INVASION; VALIDATION STUDY; BIOPSY; BLOOD; CANCER GRADING; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; EUROPE; LYMPH NODE; LYMPH NODE DISSECTION; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

BIOPSY; DECISION SUPPORT TECHNIQUES; EUROPE; HUMANS; KALLIKREINS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84920717470     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.03.013     Document Type: Article

References (33)

1. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
2. A.H. Yamada, G. Lieskovsky, Z. Petrovich, S.C. Chen, S. Groshen, and D.G. Skinner Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer Am J Clin Oncol 17 1994 277 285
3. D. van den Ouden, W.C. Hop, and F.H. Schroder Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy J Urol 160 1998 1392 1397
4. G.S. Gerber, R.A. Thisted, and G.W. Chodak Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis Eur Urol 32 1997 385 390
5. J.F. Ward, J.M. Slezak, M.L. Blute, E.J. Bergstralh, and H. Zincke Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome BJU Int 95 2005 751 756
6. S.E. Lerner, M.L. Blute, and H. Zincke Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity J Urol 154 1995 1447 1452
7. B.S. Carver, F.J. Bianco Jr., P.T. Scardino, and J.A. Eastham Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer J Urol 176 2006 564 568
8. H. Van Poppel, H. Goethuys, P. Callewaert, L. Vanuytsel, W. Van de Voorde, and L. Baert Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer Eur Urol 38 2000 372 379
9. P.J. Bastian, S.A. Boorjian, and A. Bossi High-risk prostate cancer: from definition to contemporary management Eur Urol 61 2012 1096 1106
10. S.A. Boorjian, R.J. Karnes, and R. Viterbo Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer Cancer 117 2011 2883 2891
11. S. Joniau, C.Y. Hsu, and E. Lerut A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer Eur Urol 51 2007 388 396 discussion 395-6
12. C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, and H. Van Poppel Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience Eur Urol 51 2007 121 129 discussion 128-9
13. S.E. Eggener, P.T. Scardino, and P.C. Walsh Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869 875
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guideline). Prostate cancer v.1.2011. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
15. A.W. Partin, M.W. Kattan, and E.N. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update JAMA 277 1997 1445 1451
16. D.V. Makarov, B.J. Trock, and E.B. Humphreys Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005 Urology 69 2007 1095 1101
17. D. Hosmer, and S. Lemeshow Applied logistic regression 2000 Wiley New York, NY
18. F.H. Schroder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
19. A. Bill-Axelson, L. Holmberg, and M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 364 2011 1708 1717
20. X. Zhu, P.J. van Leeuwen, M. Bul, C.H. Bangma, M.J. Roobol, and F.H. Schroder Identifying and characterizing "escapes" - men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam) Int J Cancer 129 2011 2847 2854
21. J.L. Silberstein, A.J. Vickers, and N.E. Power Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy Cancer 117 2011 4855 4860
22. L. Budaus, J. Spethmann, and H. Isbarn Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade BJU Int 108 2011 1256 1261
23. M. Bolla, H. van Poppel, and B. Tombal Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
24. A. Briganti, A. Larcher, and F. Abdollah Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores Eur Urol 61 2012 480 487
25. J. Walz, F. Bladou, and B. Rousseau Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection Urology 79 2012 546 551
26. K.H. Kim, S.K. Lim, and T.Y. Shin Upgrading of Gleason score and prostate volume: a clinicopathological analysis BJU Int 111 2013 1310 1316
27. B. Delahunt, R.J. Miller, J.R. Srigley, A.J. Evans, and H. Samaratunga Gleason grading: past, present and future Histopathology 60 2012 75 86
28. A. Sankin, B. Tareen, and H. Lepor Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy Prostate Cancer Prostatic Dis 12 2009 204 208
29. Y. Lotan, S.F. Shariat, and S.M. Khoddami The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy J Urol 171 2004 2209 2214
30. D.P. Ankerst, C. Till, and A. Boeck The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator J Urol 190 2013 70 76
31. F. Abdollah, M. Sun, and R. Thuret Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer Int J Urol 19 2012 645 651
32. M.W. Kattan, A.M. Stapleton, T.M. Wheeler, and P.T. Scardino Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma Cancer 79 1997 528 537
33. A. Briganti, S. Joniau, and P. Gontero Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer Eur Urol 61 2012 584 592